Archives
September 25, 2006
Genetics Squared Awarded $1.6 million from the 21st Century Job Fund
read more
June 19-21, 2006, San Francisco, CA
CHI's Beyond Genome 2006
Chief Technology Officer, Bill Worzel, will discuss the
use of genetic programming to discover a 3-gene signature of metastasis
in bladder cancer. This signature identifies nodal metastases from
primary tumor tissue from quantitative RT-PCR data. The method used to
discover this signature is described and the broader significance of
this approach to clinical applications including personalized medicine
is discussed.
June 18-22, 2006, Philadelphia, PA
The Drug Industry Association Annual Meeting
Genetics Squared will participate in the session chaired
by Dr. Terry Osborn where we will discuss "The Use of Genetic
Programming to Identify Biomarkers Associated with Metastasis in
Bladder Cancer." This is a collaboration with the Richard Cote
Laboratory of the University of Southern California that discovered a
simple set of biomarkers taken from quantitative RT-PCR data that
identify nodal involvement from primary tumor tissue. The technology
used to develop this signature and its potential clincal impact will be
discussed.
April 19-22, 2005, San Francisco, CA
CHI's Molecular Medicine Tri-Conference
See
Business Development Officer, Dr. Philip Wallace, discuss personalized
medicine utilizing Genetics Squared's evolutionary drug developmentTM technology at the Emerging Company Partnering Showcase.
June 13-14, 2005, Washington, DC
CHI's Targeted Therapeutics Summit
John
Freshley, CEO, will lead a distinguished panel in an interactive
discussion regarding "Why oncology in the beachfront for targeted
therapeutics."
June 16, 2005, Ann Arbor, MI
Michigan Growth Capital Symposium
John Freshley, CEO, will present Genetics Squared to an audience of leading investors.
June 20, 2005, Philadelphia, PA
BIO 2005 Business Forum
John Freshley, CEO, will present Genetics Squared to an audience of potential business partners and investors.
September 27-28, 2005, Redwood Shores, CA
Venture One's Health Care Ventures 2005
John
Freshley, CEO, will join a distinguished panel on leading industry CEOs
and venture capitalists to discuss the future of personalized medicine.
Freshley will also present Genetics Squared's business plans in a
separate presentation.
April 21, 2005
Genetics Squared announces Randal Charlton to Board of Directors.
read more
April 5, 2005
Genetics Squared announces addition of two clinical research experts to Scientific Advisory Board.
read more
January 6, 2005
Genetics Squared appoints seasoned industry managers to scientific leadership positions.
read more
October 8, 2004
Genetics Squared announces newly formed scientific advisory board
read more
September 30, 2004
Genetics Squared invited to speak at BioContact Quebec 2004
read more
July 19, 2004
Genetics Squared moves Headquarters to the Fifth Avenue Property in downtown Ann Arbor
read more
Sept 27-28, 2004
The Next Phase of Pharmacogenomics
See John Freshley, CEO, and one of our scientific collaborators, Richard Cote from the University of Southern California discuss the application of Genetics Squared's technology to identify the molecular signatures of bladder cancer.
Oct 6-8, 2004
BioContact, Quebec City, Quebec
John Freshley, CEO, has been invited to present at Canada's largest biotechnology investor conference.
Oct 19-20, 2004
VentureOne Exchange, Boston, MA
John Freshley, CEO, will join a panel of leading venture capitalists and CEOs to discuss the future of personalized medicine.
|
